SARS-CoV-2 is responsible for the 2020 global coronavirus disease 2019 (COVID-19) pandemic . In patients with COVID-19, multiple cardiovascular (CV) manifestations have been reported . SARS coronavirus 2 infection can lead to inflammatory CV disease first via takeover of the angiotensin-converting enzyme-2 enzyme as a cell receptor as well as the macrophage activation syndrome in severe illness . We review the CV manifestations of COVID-19 and therapeutics under investigation . We discuss the potential long-term CV sequelae after recovery from COVID-19 and the gaps in knowledge including the pathophysiological links between acute cardiac injury, myocardial inflammation and chronic cardiomyopathy . Future investigational efforts could result in significant diagnostic and therapeutic advances potentially impacting the broader field of chronic heart failure and cardiac recovery.Lay abstract COVID-19 has led to a global pandemic, and many patients infected with this novel virus develop cardiovascular (CV) complications including heart attacks, strokes, heart failure and sudden cardiac death . We will review the pathophysiology behind how a viral infection can place a patient at risk and cause multiple CV diseases . Additionally, we will review our current knowledge regarding treatment for the novel corona virus and long-term risk for patients who recover from COVID-19 . At last, we will discuss the future perspective regarding what we can learn about how a virus can cause CV disease and how we can better equip ourselves for future pandemics.
Index: COVID-19, cardiomyopathy, cardiovascular system, myocardial injury, myocarditis